Breaking World Pharma News

Ebola whole virus vaccine shown effective, safe in primates

An Ebola whole virus vaccine, constructed using a novel experimental platform, has been shown to effectively protect monkeys exposed to the often fatal virus. The vaccine, described in the journal Science, was developed by a group led by Yoshihiro Kawaoka, a University of Wisconsin-Madison expert on avian influenza, Ebola and other viruses of medical importance.

Read more...

AstraZeneca joins Genomics England consortium

AstraZenecaAstraZeneca has joined a public-private consortium with Genomics England to accelerate the development of new diagnostics and treatments arising from the 100,000 Genomes Project. The GENE Consortium (Genomics Network for Enterprises Consortium) is a unique partnership between industry, academia and the National Health Service (NHS) Genomic Medicine Centres,

Read more...

New MIND diet may significantly protect against Alzheimer's disease

A new diet, appropriately known by the acronym MIND, could significantly lower a person's risk of developing Alzheimer's disease, even if the diet is not meticulously followed, according to a paper published online for subscribers in March in the journal Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

Read more...

GSK's 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships with academics in Europe, Canada and US

GlaxoSmithKlineGSK is encouraging academic scientists in Europe, Canada and the US to submit their novel early drug discovery research proposals into its third annual Discovery Fast Track Challenge - a programme designed to accelerate the translation of early-stage research into game-changing new medicines.

Read more...

AstraZeneca to collaborate with the Harvard Stem Cell Institute in diabetes

AstraZenecaAstraZeneca today announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca's compound library in the search for new treatments for diabetes.

Read more...

Bristol-Myers Squibb acquires exclusive license from Novo Nordisk for a discovery research program focused on autoimmune diseases

Bristol-Myers SquibbBristol-Myers Squibb Company (NYSE:BMY) today announced the company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.

Read more...

Pfizer and Lilly preparing to resume Phase 3 chronic pain program for Tanezumab

PfizerPfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.

Read more...

World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]